Compartir
The Handbook of Psychopharmacology Trials: An Overview of Scientific, Political, and Ethical Concerns (en Inglés)
Marc Hertzman M.d. (Autor)
·
New York University Press
· Tapa Dura
The Handbook of Psychopharmacology Trials: An Overview of Scientific, Political, and Ethical Concerns (en Inglés) - Marc Hertzman M.D.
130,14 €
136,99 €
Ahorras: 6,85 €
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Estados Unidos
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Jueves 06 de Junio y el
Martes 25 de Junio.
Lo recibirás en cualquier lugar de España entre 1 y 5 días hábiles luego del envío.
Reseña del libro "The Handbook of Psychopharmacology Trials: An Overview of Scientific, Political, and Ethical Concerns (en Inglés)"
Each year pharmaceutical companies invest billions of dollars in clinical trials of drugs used for the treatment of central nervous system diseases. Due to enormous progress in basic pharmaceutical research in recent years, controlled tests of new medications are flourishing and these trials have rapidly become an intense focus of practical medical research. Aware of the complexities presented in the design, execution, and evaluation of clinical trials, Marc Hertzman and Douglas E. Feltner bring together a collection of essays that dissect the scientific, psychosocial, political, and ethical concerns that must be examined for any CNS trial. The internationally known contributors examine concerns about ethics and cost; the FDA and its regulatory impact; and the implementation of a variety of trials, for disorders such as schizophrenia, alcoholism, eating disorders, insomnia, and aggression. The editors carefully consider important social issues including the considerations related to women's special needs; and the relative merits of psychotherapy and medications. The Handbook of Psychopharmocology Trials provides an up-to- date and stimulating exploration of important issues on the subject of CNS Clinical trials.
